Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

5-HT7 receptors.

David R Thomas1, Jim J Hagan

  • 1Department of Biology, Psychiatry Centre of Excellence for Drug Discovery, GlaxoSmithKline, Harlow, Essex, UK.

Current Drug Targets. CNS and Neurological Disorders
|February 18, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Nuclear Transporter Transportin-3 Functions Under Oxidative Stress.

Cells·2026
Same author

A new taxonomy of social support: Clarifying supportive behaviours and measures.

Journal of health psychology·2026
Same author

Intralysosomal pathogens differentially influence the proteolytic potential of their niche.

Infection and immunity·2025
Same author

Coxiella burnetii manipulates the lysosomal protease cathepsin B to facilitate intracellular success.

Nature communications·2025
Same author

Coxiella burnetii protein CBU2016 supports CCV expansion.

Pathogens and disease·2024
Same author

<i>Coxiella</i> co-opts the Glutathione Peroxidase 4 to protect the host cell from oxidative stress-induced cell death.

Proceedings of the National Academy of Sciences of the United States of America·2023
Same journal

Partial QSAR analysis of some selected natural inhibitors of FAAH suggests a working hypothesis for the development of endocannabinoid-based drugs.

Current drug targets. CNS and neurological disorders·2005
Same journal

Therapeutic perspectives of inhibitors of endocannabinoid degradation.

Current drug targets. CNS and neurological disorders·2005
Same journal

Pharmacological properties and therapeutic possibilities for drugs acting upon endocannabinoid receptors.

Current drug targets. CNS and neurological disorders·2005
Same journal

Cannabinoids: between neuroprotection and neurotoxicity.

Current drug targets. CNS and neurological disorders·2005
Same journal

From cannabis to endocannabinoids in multiple sclerosis: a paradigm of central nervous system autoimmune diseases.

Current drug targets. CNS and neurological disorders·2005
Same journal

Endocannabinoids in neuroimmunology and stress.

Current drug targets. CNS and neurological disorders·2005
See all related articles

The 5-HT(7) receptor, cloned in 1993, influences smooth muscle relaxation and neuronal function. Selective ligands now enable research into its therapeutic potential for psychiatric and CNS disorders, including sleep disturbances and anxiety.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Molecular Biology

Background:

  • The 5-HT(7) receptor's function in native tissues was investigated post-cloning in 1993.
  • Peripheral studies confirmed its role in smooth muscle relaxation (gastrointestinal, cardiovascular).
  • Research in the brain was limited by the lack of selective ligands until recently.

Purpose of the Study:

  • To explore the function of the 5-HT(7) receptor in various brain regions.
  • To evaluate the therapeutic potential of 5-HT(7) receptor-selective ligands.
  • To investigate the role of the 5-HT(7) receptor in circadian rhythms, sleep, and other CNS disorders.

Main Methods:

  • Utilizing newly developed 5-HT(7) receptor-selective antagonists (e.g., SB-269970-A, SB-656104-A).

Related Experiment Videos

  • Investigating the modulation of neuronal function in brain areas like the hippocampus and thalamus.
  • Examining the receptor's involvement in circadian rhythm and sleep regulation.

    • Main Results:

    • 5-HT(7) receptor antagonists modulate neuronal function in the hippocampus and thalamus.
    • Evidence suggests a role in circadian rhythm and sleep control.
    • Potential involvement in anxiety, cognitive disturbances, and migraine is indicated.

    Conclusions:

    • 5-HT(7) receptor-selective ligands show therapeutic promise for psychiatric disorders.
    • The receptor is a potential target for treating conditions with circadian rhythm and sleep disturbances.
    • Further research may lead to novel therapeutic agents targeting the 5-HT(7) receptor for CNS disorders.